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ABSTRACT Ras proteins are post-translationally modi-
fied by farnesylation. In the present investigation, we identified
an activity in crude soluble extracts of yeast cells that catalyzes
the transfer of a farnesyl moiety from farnesyl pyrophosphate
to yeast RAS2 protein. RAS2 proteins having a C-terminal
Cys-Ali-Ali-Xaa sequence (where Ali is an aliphatic amino acid
and Xaa is the unspecified C-terminal amino acid) served as
substrates for this reaction, whereas RAS2 proteins with an
altered or deleted Cys-Ali-Ali-Xaa sequence did not. A yeast
mutant, dprl/raml, originally isolated as a Ras-processing
mutant was shown to be defective in farnesyltransferase activ-
ity. In addition, another mutant, ram2, also was defective in the
transferase activity. These results demonstrate that at least two
genes, DPRI/RAMI and RAM2, are required for the farne-
syltransferase activity in yeast.
Prenylation has been observed with a variety of proteins,
including yeast mating peptides, guanine nucleotide binding
proteins (such as Ras), and nuclear lamins (for review, see
ref. 1). A recent addition to this list is the 'y subunit ofguanine
nucleotide binding proteins (2-4). The polyisoprenoids de-
tected are either all-trans-farnesyl or all-trans-geranylgeranyl
groups (5, 6).
Farnesylation of Ras proteins (7-9) occurs as part of a
series of C-terminal modifications needed for membrane
association, including removal of three C-terminal amino
acids (10, 11) and carboxyl methylation of the C-terminal
cysteine (12). These modifications take place at a conserved
sequence, Cys-Ali-Ali-Xaa (Ali is an aliphatic amino acid and
Xaa is the unspecified C-terminal amino acid), which is
termed a "CAAX" box (13). Although it appears likely that
farnesylation occurs prior to amino acid removal and meth-
ylation, the order of these events has not been established.
Yeast mutants defective in the processing of Ras proteins
have been isolated. The dprl (14) and ram (15) mutants were
independently isolated but were shown to be allelic. (This
mutant will be called dprl/raml hereafter). Nonmodified Ras
proteins accumulate in the mutant strains (14-16), suggesting
that an early step that includes farnesylation is blocked. The
mutant strains are temperature-sensitive for growth and show
reduced mating efficiency. The effect on mating is severe in
MATa cells, since the processing of the a-factor mating
peptide is blocked (14, 15). The processing of Ras proteins is
also blocked in hmgl hmg2 double mutants (9). These
mutations abolish 3-hydroxy-3-methylglutaryl coenzyme A
reductase activity, thus affecting the production of farnesyl
pyrophosphate, which is needed for the farnesylation of Ras
proteins.
We have detected an activity in crude soluble extracts of
yeast cells that catalyzes the farnesylation of yeast RAS2
protein. This activity is deficient in dprl/raml mutant
strains. We further report the isolation of a mutation in a
second gene, termed ram2, which also causes a defect in the
farnesylation of Ras proteins. The availability of mutants
affecting Ras processing points to the usefulness of the yeast
system in analyses of protein farnesylation.
MATERIALS AND METHODS
Materials. [35S]Methionine was purchased from ICN (Trans-
35S-label; 1199 Ci/mmol; 1 Ci = 37 GBq). [3H]Farnesyl
pyrophosphate (0.5 Ci/mmol) was synthesized by the method
described (17) or was purchased from NEN (20 Ci/mmol). The
purity of farnesyl pyrophosphate was checked by thin layer
chromatography (17). Plasmids YCpl9DPR1 (16),
YEp51RAS2 (18), and YEp24DPR1 (19) have been described.
YEpDPR1 was constructed by inserting a 4.8-kilobase
BamHI-Sal I DPR1 fragment into pYS1, which contained the
2-,m origin, TRPI, and pBR322. YRpDPR1 was constructed
by inserting the above DPRI fragment into YRp7 (20).
Yeast Strains and Preparation of Crude Soluble Extracts.
The following Saccharomyces cerevisiae strains were used.
UC100 (MATa leu2 trpl ura3 pep4 prb) is described (19).
KMY5-2A (MATa dprl his3 leu2 ura3) was derived from the
cross ofHR12 (MA Ta leu2 his3 ura3 trpl ade8 can/ RAS2"""19
dprl) (14) with wild-type strains. KMY2-3A (MA Ta leu2 his3)
was the wild-type strain used for the final cross. KMY200-
sgp2-No.2-1213 (MA Ta ura3 his3 dprl:: URA3) was provided
by K. Matsumoto (DNAX); the disruption is described by
Nakayama et al. (21). STS39 (MATa rasl::URA3 RAS2"'"'9
ram2 his3 leu2 ade8 trpl cani gaI2) was isolated by S.P. as
a suppressor of the heat-shock sensitivity of RAS2""119 cells,
PT1-6 (15). STS39 was crossed with RS16-4C (MATa ura3
his3 trpl ade8 ade2 cani SUP&IL) (15) and the resulting
diploid was sporulated to yield RS51-3A (MA Ta ram2 his3
ura3 ade8 trpl canl ade2 RAS2"a19) and RS51-6C (MATa
ram2 his3 ura3 ade8 trpl cani ade2). JRY1593 (MATa ade2
met his3 lys2 ura3 hmgl::LYS2 hmg2::HIS3) and its parent
JRY1594 (MATa ade2 met his3 lys2 ura3) were provided by
J. Rine (University ofCalifornia, Berkeley). Genetic analyses
were carried out according to standard methods (20). To
facilitate the mating of dprl and ram2 strains, the dprl strain
KMY5-2A-N (MA Ta dprl his3 leu2 ura3; derived from
KMY5-2A by HO-mediated mating type switch) was trans-
formed with either YEp24 DPR1 or YCpl9DPR1. Presence of
the plasmid-borne wild-type DPRI gene complemented the
a-specific mating defect of KMY5-2A-N, allowing efficient
mating with the ram2 strain RS51-3A and RS51-6C. Diploids
Abbreviation: Ali, aliphatic amino acid.
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were selected by plating on medium lacking both leucine and
tryptophan. Ura- isolates (which had lost the DPRI plasmid)
were obtained and used in complementation studies and
tetrad analysis.
Crude soluble extracts were prepared as follows. Cells
(100-ml culture) grown in YPD medium to late logarithmic
phase were resuspended in 0.2 ml of 0.1 M Mes-NaOH, pH
6.5/0.1 mM MgCl2/0.1 mM EGTA/1 mM /3-mercapto-
ethanol/2 mM phenylmethylsulfonyl fluoride and broken
with glass beads. The extracts were then subjected to high-
speed centrifugation at 100,000 x g for 1 hr in a 70 Ti rotor
after removing cell debris by low-speed centrifugation. The
resulting supernatant had a protein concentration of '10
mg/ml.
Preparation of RAS2CT Proteins. A truncated form of
RAS2 protein, which is more stable than the full-length RAS2
protein, was expressed in Escherichia coli from plasmid
pKH502-RAS2CT1. This plasmid is identical to pKH502-
RAS2 (18) except that it contains a HincII-Bal I fragment of
RAS2 (corresponding to the N-terminal 210 amino acid
residues). At the Bal I site of the RAS2 gene, complementary
synthetic oligonucleotides were added that restored the orig-
inal C-terminal 6 amino acid residues. pKH502-RAS2CT2,
expressing a RAS2 protein with a cysteine to serine alteration
in the CAAX box, was constructed in the same way using a
pair of oligonucleotides containing the appropriate base
change. Addition of a termination codon instead of the above
oligonucleotides produced a construct, RAS2CTT, express-
ing a RAS2 protein with no CAAX box. A plasmid expressing
f-RAS2CT1 was constructed by fusing the RAS2CTI gene
with IacZ in pUC8. Expression of the RAS2CT1, RAS2CT2,
and RAS2CTT proteins was induced by the addition of
nalidixic acid. f-RAS2CT1 expression was induced by iso-
propyl /3-D-thiogalactopyranoside. E. coli cells expressing
these proteins were broken by sonication, and the proteins
were purified to near homogeneity by DEAE-Sepharose
followed by Sephadex G-75 columns in a manner similar to
that described (22). To express RAS2CT1 protein in yeast,
the RAS2CTI gene was placed under the control of the
GALIO promoter on YEp51 (18).
Farnesyltransferase Reaction and Product Analyses. Farne-
syltransferase activity was assayed by incubating RAS2
proteins with [3H]farnesyl pyrophosphate. A typical reaction
mixture of 30 ,ul contained 50 mM potassium phosphate (pH
7.4), 5 mM dithiothreitol, 10 mM MgCI2, 0.8 ,uM [3H]farnesyl
pyrophosphate (20 Ci/mmol was used if not indicated), 30 ,g
ofRAS2CT1 protein, and 50 ,ug of crude soluble extracts. The
reaction mixture was incubated at 300C. To assay for the
incorporation of radioactivity into acid-insoluble products,
the reaction mixture was spotted onto Whatman no. 3 paper,
immersed into 10% (wt/vol) trichloroacetic acid twice, and
washed twice each with ethanol and acetone. The filters were
dried and radioactivity was measured by using Liquifluor
(Amersham) as the counting solution. Analyses by SDS/
polyacrylamide gel and immunoprecipitation using Y13-259
were carried out as described (18). To determine the structure
of the transferred polyisoprenoid, the radioactive band on a
SDS/polyacrylamide gel was cut out and the radioactivity
was released by incubation with trypsin (100 Ag/ml) in 50mM
ammonium bicarbonate. After Iyophilization, the sample was
solubilized in 400 ,l of formic acid/ethanol, 1:4 (vol: vol),
and 50 mg of Raney nickel and 1 ml of pentane were added.
The sample was incubated for 15 hr at 1000C in a tightly sealed
screw cap tube. After cooling at -200C for 1 hr, 400 ,1 ofH20
was added. Then, the sample was vortex mixed and then
centrifuged for 1 min at 1500 x g, and the pentane phase was
removed. The concentrated sample was analyzed by radio-
metric GC both before and after hydrogenation over Pt (23).
RESULTS
Detection of Yeast Farnesyltransferase Activity. To detect
farnesylation of yeast RAS proteins, we used a RAS2 protein
that had an internal deletion in the C-terminal hypervariable
domain but retained the C-terminal 6 amino acid residues
Gly-Cys-Cys-Ile-Ile-Ser. This truncated RAS2 protein,
termed RAS2CT1, is functional in yeast, since its expression
complements the growth defect of ras2- cells (24) on non-
fermentable carbon sources (data not shown). RAS2CT1 was
expressed in E. coli and purified.
Incubation of RAS2CT1 protein and [3H]farnesyl pyro-
phosphate in the presence of crude extracts of yeast cells
resulted in the incorporation of radioactivity into acid-
insoluble products (Fig. 1 and also Table 1). Little incorpo-
ration occurred when no protein was added to the extracts.
This was presumably because (i) the amount of endogenous
protein was much less than that of the exogenously added
protein and/or (ii) the endogenous proteins were already
farnesylated. Similarly, little incorporation of 3H was ob-
served when RAS2CT2, which has an amino acid alteration
from cysteine to serine within the CAAX box, was used. A
RAS2 protein lacking the CAAX box (RAS2CTT) also did not
support farnesylation (data not shown). These results
strongly suggest that the famesyltransferase activity recog-
nizes the CAAX box.
Radioactivity Is Incorporated into RAS2 Protein. Fig. 2
demonstrates that the farnesyl radioactivity was incorpo-
rated into RAS2 protein. A radioactive band having an
apparent molecular mass of 30 kDa, corresponding to the
molecular mass of the RAS2CT1 protein, was detected on a
SDS/polyacrylamide gel (lane 2). This band was not detected
with the RAS2CT2 reaction (lane 3). When a fusion RAS2
protein, f-RAS2CT1, having an additional 20 amino acids at
the N terminus of the CT1 protein was used instead of
RAS2CT1, a radioactive band on a SDS/polyacrylamide gel
appeared at a position slightly higher than that seen with
RAS2CT1, reflecting the molecular mass increase (lane 5). In
addition, the radioactivity incorporated could be immuno-
precipitated with a monoclonal antibody (Y13-259) against
Ras proteins (data not shown).
The incorporated radioactivity consisted exclusively of a
C15 farnesyl moiety. This was shown by releasing the incor-
porated radioactivity by treatment with Raney nickel and
subjecting it to GC analyses. As shown in Fig. 3, the
radioactivity recovered in the nonhydrogenated sample co-
eluted with authentic all-trans-2,6,10-trimethyl-2,6,10-
dodecatriene, the expected product ofRaney nickel cleavage
ofa thioether-linked farnesyl group. After hydrogenation, the
radioactivity coeluted with farnesane.
The farnesyltransferase activity was not detected in the
presence of EDTA, suggesting that Mg2" or other divalent
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FIG. 1. Transfer of a farnesyl group from [3H]farnesyl pyrophos-
phate to RAS2CT1 protein. Farnesyltransferase reactions (90 IA)
were carried out using crude soluble extracts of UC100 cells with
RAS2CT1 (A), RAS2CT2 (A), or with no protein (x). After incuba-
tion at 300C, 20 jul were taken out at various time points and the
incorporation of radioactivity into acid-insoluble products was de-
termined by a filter binding assay and presented as cpm x 10-3.
Proc. Natl. Acad. Sci. USA 87 (1990)
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Table 1. Mutant extracts do not inhibit farnesyltransferase
[PH]Farnesyl
incorporated,
Exp. Extract(s) cpm
1 WT (17 Mg) 44,345
WT (34 Ag) 66,164
dprl (17 Mg) 7,576
WT (17 pg) + dprl (17 Ag) 37,3%
No protein control 3,550
2 WT (8 ,g) 17,379
ram2 (15 Mg) 1,700
WT (8 Ag) + ram2 (8 Mg) 15,306
No protein control 1,262
In experiment 1, UC100 and KMY5-2A cells were used for
wild-type (WT) and dprl cells, respectively. Farnesyltransferase
reactions were carried out with RAS2CT1 protein at 300C for 30 min.
In experiment 2, RS16-4C and RS51-3A cells were used for wild-type
(WT) and ram2 cells, respectively, with incubations at 30'C for 20
min. For both experiments, the total amount of extract protein per
10 Ml is indicated in parentheses.
cations are required. Dithiothreitol stimulated the activity
:=2-fold. The transferase activity was detected in a pH range
of pH 5.5 to 8 with an optimum of pH 6.5 in Mes buffer.
Incubation temperatures between 250C and 450C supported
the activity, but little activity was detected at 150C.
Yeast Mutants Defective in Farnesyltransferase. To gain
insight into the genes involved in the farnesylation of Ras
proteins, we sought to find mutants defective in farnesyl-
transferase. One candidate was dprl/raml, known to be
defective in the processing of Ras proteins (14, 15). This
mutation is within the DPRl/RAM1 gene, which encodes a
hydrophilic protein of 431 amino acids (16). In addition,
another mutant, termed ram2, has been isolated. The mutant
was obtained as a second site suppressor of heat-shock
sensitive RAS2VaII9 yeast cells. (Detailed characterization of
ram2 will be published elsewhere.) The ram2 mutation is
recessive and causes temperature-sensitive growth. Pro-
cessing of the RAS2 protein is defective in the mutant and
a-factor production is greatly reduced (unpublished results).
Both the dprl/raml and ram2 mutants were defective in
farnesyltransferase activity. As shown in Fig. 4 A and B,
virtually no incorporation of farnesyl radioactivity into the
RAS2 protein was detected in either the dprl/raml extracts
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FIG. 2. SDS/polyacrylamide gel electrophoresis of the products
of farnesyltransferase reaction. Farnesyltransferase reactions were
carried out at 300C with [3H]farnesyl pyrophosphate (0.5 Ci/mmol).
The entire sample from each reaction mixture (30 Al) was then
analyzed on a 12.5% polyacrylamide gel containing SDS. Lanes: 1,
UC100 extracts (50 Mg) alone; 2, UC100 extracts (50 Ag) + RAS2CT1
(7 pg); 3, UC100 extracts (50 Ag) + RAS2CT2 (7 Mg); 4, KMY2-3A
extracts (121 Ig) + RAS2CT1 (7prg); 5, KMY2-3A extracts (121 .-g)
+ f-RAS2CT1 (7 Mg). Molecular mass markers indicated are oval-
bumin (46 kDa), carbonic anhydrase (30 kDa), and lysozyme (14
kDa).
Time (min)
FIG. 3. Identification of the isoprenoid transferred to RAS2CT1.
The farnesyltransferase reaction was catalyzed by UC100 extracts
and RAS2CT1 protein. The radioactivity incorporated into
RAS2CT1 protein was identified on a 12.5% polyacrylamide gel
containing SDS. The radioactivity was eluted from the gel and was
analyzed by GC. (A) Nonhydrogenated 3H-labeled material released
from RAS2CT1. (B) Authentic all-trans-2,6,10-trimethyl-2,6,10-
dodecatriene with trace amounts of other cis/trans isomers (23). (C)
3H-labeled material released from RAS2CT1, which had been hy-
drogenated over platinum. (D) Authentic farnesane. No C20 iso-
prenoid was observed (all-trans-2,6,10,14-tetramethyl-2,6,10,14-
hexadecatetraene, tR = 43.9 min; phytane, tR = 38.3 min).
or the ram2 extracts. Similar results were obtained with other
dprl alleles including a gene disruption and a complete
deletion (data not shown). Lack of detectable farnesyltrans-
ferase activity was not due to the presence ofany endogenous
inhibitors, since mixing the mutant and wild-type extracts did
not significantly reduce wild-type activity (Table 1). At-
A
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FIG. 4. Farnesyltransferase activity in yeast mutants. The far-
nesyltransferase reaction was carried out at 30'C using RAS2CT1
protein. Cell extracts were used as indicated below. After various
incubation periods, samples were spotted onto filter papers and
acid-insoluble radioactivity was determined. (A) KMY5-2A (dprl)
(e) and KMY2-3A (o). (B) RS51-3A (ram2) (m) and RS16-4C (a). (C)
JRY1593 (hmgl hmg2) (A) and JRY1594 (A). Data for 3H incorpo-
ration are presented as cpm x 10-3.
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tempts to recover farnesyltransferase activity by mixing the
dprl/raml and ram2 extracts have been unsuccessful (see
Discussion).
Three lines of evidence support the hypothesis that dprl/
ramI and ram2, although having similar phenotypes, are two
different mutations. (i) dprl and ram2 belong to different
complementation groups. This was demonstrated by crossing
dprl and ram2 strains. Seven diploids resulting from the
crosses were screened for temperature sensitivity; all grew at
the nonpermissive temperature (37TC), even though the in-
dividual mutants were temperature-sensitive for growth.
Extracts prepared from the diploids exhibited farnesyltrans-
ferase activity significantly above the mutant level (data not
shown). (ii) These diploids were sporulated and tetrads were
dissected. Due to poor sporulation efficiency and poor spore
viability (56% overall), only six complete tetrads were ana-
lyzed. (The reasons for the low spore viability are unknown;
however, multiple factors are known to affect sporulation and
spore viability. It is possible that temperature-sensitive
spores have decreased viability even at the permissive tem-
perature.) The ability to grow at 370C segregated 0+:4- in one
tetrad, 1+:3- in three tetrads, and 2+:2- in two tetrads,
consistent with the pattern expected for mutations in two
different genes. (If the two mutations were in the same gene,
the expected segregation pattern would be all 0+:4-.) The
third line of evidence indicating that dprl/raml and ram2 are
nonallelic is shown in Fig. 5. The temperature-sensitive
growth of the dprl mutant can be complemented by either a
single-copy DPR1 plasmid (YCpDPR1) or a multicopy DPR1
plasmid (YRpDPR1). In marked contrast to this, the temper-
ature-sensitive growth of the ram2 mutant was comple-
mented neither by a single-copy DPR1 plasmid (YCpDPR1)
nor by multicopy DPR1 plasmids (YEpDPR1 or YRpDPR1).
Farnesylation ofRas Proteins in hmgl hmg2 Double Mutants
Is Blocked in Vivo but Not in Vitro. The hmgl and hmg2
mutations affect mevalonate production, thus limiting the
supply offarnesyl pyrophosphate (9). Extracts prepared from
the hmgl hmg2 double mutant, however, were active in the
farnesylation of Ras proteins in vitro (Fig. 4C). The mutant
extracts were prepared from cells grown in the presence of
mevalonic acid (5 mg/ml) and then starved for mevalonic acid
for 3 hr before collection. Such starvation blocks the pro-
cessing of Ras proteins in vivo (9).
DISCUSSION
Crude soluble extracts of yeast cells catalyze the addition of
a farnesyl moiety to the RAS2 protein. The C-terminal
FIG. 5. Lack of complementation of the temperature-sensitive
growth of ram2 mutant with cloned DPRI gene. KMY200-sgp2-
No.2-1213 (dprl) or STS39 (ram2) cells were transformed with the
DPR1 plasmids as follows. Rows: 1, YCpDPR1/dprl; 2, YCpDPR1/
ram2; 3, YEpDPR1/ram2; 4, YRpDPR1/ram2; 5, YRpDPR1/dprl.
After growing the transformants under nutritional selection, the cells
were replica plated onto YPD and incubated at 37°C.
DPR) RAM2
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FPP s
MVA
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FIG. 6. Schematic representations of three yeast genes involved
in farnesyltransferase. DPRI and RAM2 genes appear to affect the
farnesyltransferase directly, rather than altering the supply of far-
nesyl pyrophosphate (FPP) as for HMGI,2 genes. Whether they
encode subunits of the enzyme has not yet been elucidated. MVA,
mevalonic acid.
sequence of the RAS2 protein is required for the activity as
evidenced by the inability of RAS2 proteins having a mutated
CAAX box (alteration of cysteine to serine within the CAAX
box or deletion of the CAAX box) to serve as substrates. The
6 C-terminal amino acids are sufficient for recognition of the
substrate, as indicated by our use of a truncated RAS2
protein retaining only the last 6 amino acids of the C-terminal
domain. These observations are in line with the proposal that
the CAAX box is important for the modification of Ras
proteins.
A similar activity in rat brain has been purified to near
homogeneity (25). Properties of this rat enzyme including the
requirement for Mg2+ and the CAAX box are very similar to
those of the yeast enzyme. In addition, we have shown that
extracts prepared from Schizosaccharomyces pombe cells
exhibit a similar activity (J. Brown and F.T., unpublished
data). Thus, farnesyltransferase appears to be a ubiquitous
eukaryotic enzyme.
Yeast provides an ideal system for the genetic analysis of
Ras farnesylation. Three genotypes, dprl/raml, ram2, and
hmgl hmg2 , are known to affect processing of Ras proteins
in vivo (9, 14, 15). The hmgl hmg2 mutations limit the supply
of farnesyl pyrophosphate but do not affect farnesyltrans-
ferase activity, since addition of farnesyl pyrophosphate to
the in vitro assay allows full farnesyltransferase activity. In
marked contrast to this, the dprl/raml and ram2 mutants are
still defective in the in vitro farnesyltransferase assay 11; these
mutations affect a different step in the farnesylation of Ras
proteins than does hmgl hmg2. These points are presented
schematically in Fig. 6 to contrast the various steps that these
genes affect.
One striking aspect of our finding is that we have identified
two distinct mutants that affect yeast farnesyltransferase
activity. Either mutation alone drastically reduces this ac-
tivity, rather than partially diminishing it. Thus, it appears
that at least two genes are required for farnesyltransferase
activity. Our observation that overexpression of only one
gene, DPRI, does not result in an increase of farnesyltrans-
ferase activity is consistent with the hypothesis above
(L.E.G. and F.T., unpublished data).
A possible reason why two genes are required for the yeast
farnesyltransferase is that they encode subunits of the en-
zyme. The farnesyltransferase purified from rat brain has an
apparent molecular mass of 70-100 kDa and contains equi-
molar amounts of two polypeptides of -50 kDa (25). The
yeast enzyme might have a similar structure. However, we
have not been successful in recovering farnesyltransferase
activity by mixing the dprl and ram2 extracts. This might be
because we have not found the right conditions for reconsti-
"While this paper was under review, a report describing defective
farnesyltransferase activity in extracts prepared from dprl/raml
mutant appeared (26).
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tution or because the subunits are stable only when both are
present. Although we favor the hypothesis that the DPRI and
RAM2 encode subunits of farnesyltransferase, it is also
possible that one or both of these genes affect the expression
or activity ofthe transferase. Purification ofthe yeast enzyme
should provide clues to these questions.
Farnesyltransferase presumably contains two functional
domains; one recognizing one or more elements of the CAAX
box and another recognizing farnesyl pyrophosphate. Yeast
mutants defective in famesyltransferase activity described
here as well as other mutants that can be generated should
provide valuable tools for structural and mechanistic studies
of this type of enzyme.
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